PB006: A Natalizumab Biosimilar - Shirley, Matt (Clinical drug investigation, 2024)
Keywords: Adis Biosimilar Brief; Antibodies; Biological products; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - pharmacokinetics; Biosimilar Pharmaceuticals - therapeutic use; Cell adhesion & migration; Drug dosages; Humans; Internal Medicine; Magnetic resonance imaging; Medicine; Medicine & Public Health; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Natalizumab - adverse effects; Natalizumab - therapeutic use; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy